A Risk Assessment and Risk-Based Approach Review of Pre-Use/Post-Sterilization Integrity Testing (PUPSIT)

References

1. 1.↵
   International Conference for Harmonisation, Quality Guideline Q9 (R1): Quality Risk Management. ICH: Geneva, 2023.
2. 2.↵
   1. Jornitz M. W.

   Filtration Clarification Needs in Annex 1. In Pharmaceutical Technology®/Pharmaceutical Technology Europe® Quality and Regulatory Sourcebook eBook; MultiMedia Pharma Sciences LLC, 2024; pp 10–13.
3. 3.↵
   Parenteral Drug Association Inc. Technical Report No. 26: Sterilizing Filtration of Liquids; Bethesda, MD, 2008.
4. 4.↵
   U.S. Food and Drug Administration, Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice. Center for Biologics Evaluation and Research. U.S. Department of Health and Human Services: Rockville, MD, 2004.
5. 5.↵
   International Organization for Standardization, ISO 13408-2:2003(E) Aseptic Processing of Health Care Products—Part 2: Filtration. ISO: Geneva, 2003.
6. 6.↵
   Ministry of Health Labour and Welfare of Japan, Sterile Drug Products Produced by Aseptic Processing. MHLW: Tokyo, 2005.
7. 7.↵
   Pharmaceutical Inspection Convention/Cooperation Scheme (PIC/S), Recommendation on the Validation of Aseptic Processes. PIC/S: Geneva, 2004
8. 8.↵
   1. Morris T.,
   2. Jornitz M. W.,
   3. Gori G.,
   4. Baseman H.

   PUPSIT and the Annex 1 Revision. PDA Letter August 29, 2019.
9. 9.↵
   European Commission, EudraLex—The Rules Governing Medicinal Products in the European Union, Volume 4: Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use, Annex 1: Manufacture of Sterile Medicinal Products. European Commission: Brussels, 2008.
10. 10.↵
    European Commission, EudraLex—The Rules Governing Medicinal Products in the European Union, Volume 4: Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use, Annex 1: Manufacture of Sterile Medicinal Products. European Commission: Brussels, 2022.
11. 11.↵
    1. Jornitz M. W.,
    2. Meltzer T. H.

    Pre-Use/Post-Sterilization Integrity Testing of Sterilizing Grade Filter: The Need for Risk Assessment. Am. Pharm. Rev. 2011, 14 (5).
12. 12.↵
    1. Bartel K.,
    2. Baseman H.,
    3. Gori G.,
    4. Levy R.,
    5. Ly H.,
    6. Jornitz M.,
    7. Madsen R.,
    8. Rook M.,
    9. Schniepp S.

    PDA Pre Use/Post-Sterilization Integrity Test Task Force; Bartel K., Baseman H., Gori G., Levy R., Ly H., Jornitz M., Madsen R., Rook M., Schniepp S. Pre-use/Post-sterilization Integrity Testing of Sterilizing Grade Filters. PDA J. Pharm. Sci. Technol. 2012, 66 (5), 394–395.

    OpenUrlFREE Full Text
13. 13.↵
    1. Ly H.

    Sterile Filtration: Clarification Proposal Annex 1 Paragraph 113: Focus on Pre-use/Post-sterilization Integrity Testing. Presented at PDA Meeting, Dublin, July 10, 2011.
14. 14.↵
    Points to Consider for Risks Associated with Sterilizing Grade Filters and Sterilizing Filtration, Parenteral Drug Association Inc.: Bethesda, MD, 2020.
15. 15.↵
    1. Ferrante S.,
    2. McBurnie L.,
    3. Dixit M.,
    4. Joseph B.,
    5. Jornitz M.

    Test Process and Results of Potential Masking of Sterilizing Grade Filters. PDA J. Pharm. Sci. Technol. 2020, 74 (5), 509–523.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    1. Thome B.,
    2. Joseph B.,
    3. Dassu D.,
    4. Gaerke J.,
    5. McBurnie L.,
    6. Dixit M.,
    7. Stering M.,
    8. Tomlinson S.,
    9. Mills S.,
    10. Ferrante S.,
    11. Weitzmann C.

    Data Mining to Determine the Influence of Fluid Properties on the Integrity Test Values. PDA J. Pharm. Sci. Technol. 2020, 74 (5), 524–562.

    OpenUrlAbstract/FREE Full Text
17. 17.↵
    Points to Consider for Implementation of Pre-Use Post-Sterilization Integrity Testing (PUPSIT). Parenteral Drug Association Inc.: Bethesda, MD, 2020.
18. 18.↵
    International Electrotechnical Commission. IEC 61025:2006 Fault Tree Analysis (FTA). IEC: Geneva, 2006.
19. 19.↵
    Parenteral Drug Association Inc. Technical Report No. 54: Implementation of Quality Risk Management for Pharmaceutical and Biotechnology Manufacturing Operations; Bethesda, MD, 2012.
20. 20.↵
    Committee for Proprietary Medicinal Products. Note for Guidance on Manufacture of the Finished Dosage Form; CPMP/QWP/486/95; EMEA: London, 1996.